Bernstein SocGen Adjusts Abbott Labs Price Target Following Q4 Sales Setback
Bernstein SocGen has revised downward its price target for Abbott Laboratories to $125 from $154, maintaining an Outperform rating. This adjustment reflects the company's unexpected decline in fourth-quarter sales and a slowing continuous glucose monitoring segment. Despite these challenges, consensus among analysts remains positive, with potential…